MX9301903A - Compuestos. - Google Patents

Compuestos.

Info

Publication number
MX9301903A
MX9301903A MX9301903A MX9301903A MX9301903A MX 9301903 A MX9301903 A MX 9301903A MX 9301903 A MX9301903 A MX 9301903A MX 9301903 A MX9301903 A MX 9301903A MX 9301903 A MX9301903 A MX 9301903A
Authority
MX
Mexico
Prior art keywords
useful
compounds
mediation
tnf
inhibition
Prior art date
Application number
MX9301903A
Other languages
English (en)
Inventor
Siegfried Benjamin Christen Iv
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX9301903A publication Critical patent/MX9301903A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)

Abstract

Se describen nuevos derivados de ciclohesan-ilideno de la fórmula (I): Estos compuestos inhiben la producción del factor de necrosis de tumor (FNT) y son útiles en el tratamiento de estados mórbidos, mediados o exacerbados por la producción de FNT. Estos compuestos también son útiles en la mediación o inhibición de la actividad enzimática o catalítica de fosfodiesterasa IV y, por consiguiente, son útiles en el tratamiento de estados mórbidos que necesiten su mediación o inhibición.
MX9301903A 1992-04-02 1993-03-05 Compuestos. MX9301903A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86211292A 1992-04-02 1992-04-02
US96876092A 1992-10-30 1992-10-30
PCT/US1993/001988 WO1993019747A1 (en) 1992-04-02 1993-03-05 Compounds useful for treating allergic and inflammatory diseases

Publications (1)

Publication Number Publication Date
MX9301903A true MX9301903A (es) 1994-08-31

Family

ID=27127669

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301903A MX9301903A (es) 1992-04-02 1993-03-05 Compuestos.

Country Status (10)

Country Link
US (1) US5602173A (es)
EP (1) EP0634930A4 (es)
JP (1) JP3195352B2 (es)
CN (1) CN1094711A (es)
AU (1) AU3738293A (es)
IL (1) IL105223A0 (es)
MA (1) MA22923A1 (es)
MX (1) MX9301903A (es)
SI (1) SI9300170A (es)
WO (1) WO1993019747A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO115872B1 (ro) * 1992-04-02 2000-07-28 Smithkline Beecham Corp Derivati substituiti ai acidului fenilcarboxilic si compozitie farmaceutica ce ii contine
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5578576A (en) * 1994-09-02 1996-11-26 Dalhousie University Method and composition for treating intestinal wounds or ulcers
WO1996018399A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Aryl thioxanthines
EP0799031A4 (en) * 1994-12-23 1998-03-25 Smithkline Beecham Corp 1,4,4- (TRISUBSTITUTE) CYCLOHEXANE DIMERES AND RELATED COMPOUNDS
WO1996019986A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 1,4,4-(trisubstituted)cyclohexane monomers and related compounds
EP0799185A4 (en) * 1994-12-23 1998-03-25 Smithkline Beecham Corp DIMERES 1,3,3- (TRISUBSTITUES) CYCLOHEXANE AND RELATED COMPOUNDS
PT828728E (pt) * 1995-05-18 2003-06-30 Altana Pharma Ag Di-hidrobenzofuranos de fenilo
US6080782A (en) * 1995-05-18 2000-06-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Cyclohexyl dihydrobenzofuranes
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US5891883A (en) * 1995-12-21 1999-04-06 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
MY118813A (en) 1997-02-12 2005-01-31 Smithkline Beecham Corp Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
EP1524268B1 (en) * 1997-02-12 2007-01-17 Smithkline Beecham Corporation Compounds and method for preparing sustituted 4-phenyl-4-cyanocyclohexanoic acids
EP1295869B1 (en) * 1997-02-12 2005-07-27 SmithKline Beecham Corporation Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
UY26268A1 (es) * 1999-08-06 2001-01-31 Smithkline Beecham Corp Procedimiento para preparar acidos a traves de alfa-cloroep xi- esteres ley 17164 art 127
US20040220424A1 (en) * 1999-08-06 2004-11-04 Smithkline Beecham Corporation Process for preparing acids via alpha-chloroepoxy esters
DE60043318D1 (de) 1999-08-21 2010-01-14 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
EP2258689A1 (en) 2000-03-16 2010-12-08 Biolipox AB Benzylated PDE4 inhibitors
RU2275359C2 (ru) * 2000-08-11 2006-04-27 Оно Фармасьютикал Ко., Лтд. Производные пиперидина и средство, содержащее производное пиперидина в качестве активного ингредиента
TW200302724A (en) * 2002-02-08 2003-08-16 Ono Pharmaceutical Co Piperiding derivative compound and pharmaceuticals containing same as active ingredient
EP1481969B1 (en) * 2002-02-08 2011-01-19 Ono Pharmaceutical Co., Ltd. Piperidine derivative compounds and drugs containing the compounds as the active ingredient
WO2004016596A1 (en) * 2002-08-19 2004-02-26 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
JP2006506379A (ja) 2002-10-23 2006-02-23 グレンマーク・ファーマシューティカルズ・リミテッド 炎症性およびアレルギー性疾患の治療に有用な新規三環式化合物：その調製方法およびそれらを含む医薬組成物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR20050115331A (ko) 2003-04-01 2005-12-07 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 불임증 포스포디에스터라제의 억제제
BRPI0409747A (pt) 2003-04-11 2006-05-09 Glenmark Pharmaceuticals Sa novos compostos heterocìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo estes
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
CA2583497A1 (en) 2004-10-13 2006-04-20 Glenmark Pharmaceuticals S.A. Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide
SI1831227T1 (sl) 2004-12-17 2013-09-30 Glenmark Pharmaceuticals S.A. Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj
KR101317119B1 (ko) 2004-12-17 2013-10-11 그렌마크 파머수티칼스 에스. 아. 염증성 및 알레르기성 장애의 치료에 유용한 신규한헤테로사이클릭 화합물
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Also Published As

Publication number Publication date
MA22923A1 (fr) 1994-04-01
EP0634930A4 (en) 1995-02-22
SI9300170A (sl) 1993-12-31
US5602173A (en) 1997-02-11
CN1094711A (zh) 1994-11-09
EP0634930A1 (en) 1995-01-25
AU3738293A (en) 1993-11-08
JPH07508261A (ja) 1995-09-14
JP3195352B2 (ja) 2001-08-06
WO1993019747A1 (en) 1993-10-14
IL105223A0 (en) 1994-08-26

Similar Documents

Publication Publication Date Title
MX9301903A (es) Compuestos.
MX9301904A (es) Compuestos.
MX9301942A (es) Derivados de ciclohexan-ilideno novedosos.
CA2133439A1 (en) Compounds useful for treating allergic and inflammatory diseases
NO20000762D0 (no) Anvendelse av substituerte adeninderivater til behandling av multippel sklerose
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
WO1993019720A3 (en) Compounds
AP9100310A0 (en) Tnf inhibitors
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
DE60041399D1 (de) Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
MY109561A (en) Compounds for treating allegic and inflammatory diseases and inhibiting the production of tumor necrosis factor tnf
ATE286892T1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
DE59202744D1 (de) 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung.
GR920100523A (el) Ενώσεις.
GB9723905D0 (en) Heterocyclic compounds having MMP and TNF inhibitory activity
GR920100521A (el) Ενώσεις.
GR3024709T3 (en) Novel cytarabine derivatives, their production and use
UY26836A1 (es) Pirrolidinas 1,3-disustituidas y 1,3,3-trisustituidas como ligandos del receptor de histamina y sus aplicaciones terapéuticas